Drug intelligence / Profile preview

BMS-986410 + BMS-986409

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

BMS-986410 + BMS-986409 is an investigational combination therapy developed by Bristol Myers Squibb for the treatment of advanced solid tumors, including metastatic castration-resistant prostate cancer. Both agents are novel immuno-oncology drugs under clinical evaluation. While detailed mechanisms of action for each agent are not fully disclosed in public sources, they are being studied together as part of a strategy to enhance anti-tumor immune responses in cancers that have progressed despite standard therapies[3][1]. The combination is currently being evaluated in early-phase clinical trials to assess safety and tolerability.

Other names: gridegalutamide

Targets

CRBN (Cereblon)AR (Adrenergic receptors)

Beyond the preview

Go deeper on BMS-986410 + BMS-986409.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986410 + BMS-986409.

Explore the full profile